ARCHIMED has acquired a majority stake in Cube, a provider of membrane protein services, to enhance its market penetration and expand product offerings in the biopharmaceutical research sector.

Information on the Target

ARCHIMED has successfully acquired a majority stake in Cube, a Monheim, Germany-based company that specializes in providing membrane protein services tailored for the biopharmaceutical research sector. Established in 2012, Cube has developed proprietary methods that enable the production of high-purity, stable membrane proteins essential for drug discovery. Membrane proteins serve as critical receptors within cells; however, their extraction is often challenging and risks compromising their native functionality. Cube's innovative techniques are central to overcoming these challenges, thereby facilitating structure determination and enhancing drug discovery efforts.

The management team at Cube, including co-founder and Managing Director Barbara Maertens, expresses enthusiasm for this partnership with ARCHIMED, emphasizing that it will enhance the company's presence in the vast U.S. drug discovery market. With the support of ARCHIMED, Cube aims to expand its product offerings and services both organically and through strategic acquisitions, further establishing itself as a leader in its specialized field.

Industry Overview in Germany

The biopharmaceutical industry in Germany plays a vital role in the country's economy, representing one of the largest sectors within its life sciences landscape. Germany boasts a strong emphasis on research and development, with numerous biotechnology firms